TBPH

Business Context and Reporting Period

Company: Theravance Biopharma, Inc. (TBPH)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: A biopharmaceutical company focused on respiratory and neurological therapeutics. Its primary commercial asset is YUPELRI (revefenacin) for COPD, co-promoted with Viatris Inc. Its lead development candidate is ampreloxetine for neurogenic orthostatic hypotension in Multiple System Atrophy (MSA). The company also holds a significant economic interest in TRELEGY (GSK) via milestone payments and future royalties.

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: Revenue is derived primarily from the Viatris collaboration agreement (35% profit share of YUPELRI US sales). Total YUPELRI net sales (100% recorded by Viatris) were $238.6 million in 2024.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 12% to $64.4 million, driven by a 13% increase in revenue from the Viatris collaboration agreement. This was fueled by an 8% increase in total YUPELRI net sales and lower costs incurred by Viatris.
• Expense Reductions:
  • R&D Expenses: Decreased 7% to $37.6 million, primarily due to a $2.9 million reduction in share-based compensation and $2.2 million in facility savings following 2023 strategic actions.
  • SG&A Expenses: Decreased 1% to $69.2 million. Excluding share-based compensation, G&A expenses dropped 15% due to cost-saving initiatives, while selling/marketing expenses increased due to pre-launch activities for ampreloxetine.
• Impairment Charges: Recognized a non-cash impairment charge of $4.5 million related to operating lease assets and leasehold improvements in South San Francisco, compared to none in 2023.
• Tax Expense: Provision for income tax expense increased to $11.8 million (from $5.9 million), primarily attributed to uncertain tax positions and interest on historical positions.

Guidance, Outlook, and Strategic Developments

• Strategic Review: In November 2024, the Board formed a Strategic Review Committee to assess all strategic alternatives (including potential transactions related to YUPELRI, ampreloxetine, and TRELEGY) to unlock shareholder value. No timetable or assurance of a transaction is provided.
• TRELEGY Milestone: In February 2025, the company received a $50.0 million milestone payment from Royalty Pharma Investments, the maximum available for 2024, triggered by TRELEGY global net sales of $3.46 billion. An additional $150.0 million in potential milestones remains available through 2026.
• Ampreloxetine Development: Enrollment in the Phase 3 CYPRESS study for MSA patients is on track for completion in mid-2025, with data expected approximately six months later.
• YUPELRI Performance: Hospital volumes grew 41% in 2024. The company settled patent litigation with five generic companies, granting them a license to launch generic versions on or after April 23, 2039. Litigation with three remaining generic companies remains pending.
• Liquidity: Management expects current cash and marketable securities ($88.4 million) to fund operations for at least the next 12 months.

Investor Verification Checklist

• Strategic Review Outcome: Monitor for announcements regarding the Strategic Review Committee's findings, as this could lead to a sale, merger, or asset divestiture.
• Ampreloxetine Phase 3 Data: Verify the timeline and results of the CYPRESS study (expected mid-2025 completion, data readout late 2025), which is critical for future revenue potential.
• Generic Competition: Track the status of pending patent litigation with the three remaining generic companies challenging YUPELRI patents.
• TRELEGY Sales Trajectory: Monitor GSK's TRELEGY sales performance to assess the likelihood of achieving the remaining $150 million in milestone payments in 2025 and 2026.
• Cash Burn Rate: Review quarterly cash flow statements to ensure the $88.4 million cash balance remains sufficient given the ongoing costs of the ampreloxetine trial and commercialization preparations.